October 2006
ICIS Chemical Business;10/2/2006, Vol. 1 Issue 37, p47
Trade Publication
The article reports that Belgian pharmaceuticals company UCB has held a technology open day in London, England. The company transformed itself from a chemicals firm two-and-a-half years ago, and is in the process of buying Schwartz Pharma. The firm has shunned pharmaceutical research trends such as high throughput screening.


Related Articles

  • COMPANY SPOTLIGHT -- Schwarz Pharma.  // PharmaWatch: CNS;Apr2007, Vol. 6 Issue 4, p19 

    The article features Schwarz Pharma, a company engaged in research and development, production, marketing, and distribution of pharmaceutical products. It has a drug development team engaged in developing drugs for the treatment of neurological and urological disorders. The company's products...

  • Schwarz: lacosamide on track for dual approval.  // PharmaWatch: Monthly Review;Jan2005, Vol. 4 Issue 1, p19 

    The article reports on the results of phase II clinical trial of lacosamide, a novel epilepsy drug from Schwarz Pharma Ag in Germany. According to the company, lacosamide generated positive results and successfully met expectations as a promising antiepileptic agent. The drug is also in late...

  • Schwarz Pharma: Neupro to improve patient convenience in Parkinson's.  // PharmaWatch: Monthly Review;Jun2007, Vol. 6 Issue 6, p14 

    The article reports on the approval given by the U.S. Food and Drug Administration (FDA) to Neupro of Schwarz Pharma AG, a transdermal patch formulation of the dopamine agonist rotigotine, for the treatment of early-stage Parkinson's disease (PD). It is stated that the approval of Neupro follows...

  • COMPANY SPOTLIGHT -- Schwartz Pharma.  // PharmaWatch: Monthly Review;Apr2007, Vol. 6 Issue 4, p27 

    The article profiles Schwarz Pharma Inc., a pharmaceutical company involved in the development and marketing of drugs for the treatment of central neurology, cardiovascular and gastro intestinal diseases. The company's research and development teams are grouped together under Schwarz Biosciences...

  • Schwarz Pharma stays positive.  // Life Science Today;Dec2000, Vol. 1 Issue 6, p6 

    Reports on the decline of the profits earned by Schwarz Pharma in Germany.

  • UCB tender shortfall. Gibson, Jane // ICIS Chemical Business;1/8/2007, Vol. 2 Issue 48, p8 

    This article states that pharmaceuticals major UCB has received tenders amounting to 87.62% of the total outstanding share capital of Schwarz Pharma after the offer period ended on 28 December 2006. Shareholders of Schwarz Pharma who had tendered their shares during the final acceptance period...

  • Parkinson's Disease Update.  // PharmaWatch: CNS;Mar2005, Vol. 4 Issue 3, p6 

    The article offers news briefs related to the pharmaceutical industry. GB Therapeutics Ltd. has signed an exclusive license agreement to Chiesi Farmaceutici's CHF1512 molecule. Schwarz Pharma has re-submitted a modified new drug application for its rotigotine patch Neupro to the U.S. Food and...

  • Company Overview.  // Schwarz Pharma AG SWOT Analysis;Sep2005, p4 

    Presents an overview of Schwarz Pharma AG, a publicly traded pharmaceutical company which develops and markets drugs with a focus on central neurology and cardiovascular diseases. Revenues generated in fiscal year 2002; Principal business offered, including the development of drugs used to treat...

  • Schwarz Pharma AG SWOT Analysis.  // Schwarz Pharma AG SWOT Analysis;Mar2006, p1 

    Presents an overview of Schwarz Pharma AG, a pharmaceutical company that develops and markets drugs with a focus on central neurology and cardiovascular diseases. Company overview, including revenues generated in fiscal year ended December 2005, services provided, and principal businesses; Key...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics